HALO News and Press, Halozyme Therapeutics Inc. From 08/08/23

2023-08-08 16:04:28 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.74 beats by $0.10 . Revenue of $221.04M (+45.1% Y/Y) beats by $21.09M . Royalty Revenue Increased 31% YOY to Record $111.7 million 2023 Outlook: Total rev...

HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Revenue Increased 45% YOY to $221.0 million ; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1 Royalty Revenue Increased 31% YOY to Record $111.7 millio...

2023-08-07 17:35:58 ET Halozyme Therapeutics ( NASDAQ: HALO ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is $0.64 (+20.8% Y/Y) and the consensus Revenue Estimate is $199.95M (+31.2% Y/Y). Over the...

Halozyme To Report Second Quarter 2023 Financial and Operating Results PR Newswire SAN DIEGO , July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating re...

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO , July 17, 2023 /PRNewswire/ -- Halo...

2023-07-13 09:29:04 ET TG Therapeutics ( NASDAQ: TGTX ), the developer of FDA-approved multiple sclerosis therapy Briumvi, lost ~10% pre-market Thursday after Genentech, a unit of Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), said Thursday that its product Ocrevus reached its m...

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis PR Newswire SAN DIEGO , July 13, 2023 /PRNewswire/ -- Halozyme Thera...

2023-07-05 06:24:36 ET Summary argenx's Vyvgart Hytrulo, a game-changer with its 1-minute SC formulation, opens a new revenue stream for Halozyme with sales expected to surpass $10Bn. Despite past headwinds, Vyvgart's SC approval and potential co-formulation patent disclosure coul...

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis PR Newswire VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) ...

2023-06-19 07:44:24 ET Summary Halozyme Therapeutics' valuation has declined, providing a more attractive entry point for investors. The company has multiple royalty-producing products and two new ones awaiting approval in 2023. Halozyme has a strong pipeline of products in de...